Stifel Upgrades eFFECTOR Therapeutics to Buy, Raises Price Target to $7
Portfolio Pulse from richadhand@benzinga.com
Stifel analyst Benjamin Burnett upgraded eFFECTOR Therapeutics (NASDAQ:EFTR) from Hold to Buy and raised the price target from $1.3 to $7.
May 26, 2023 | 12:21 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Stifel upgraded eFFECTOR Therapeutics to Buy and raised the price target from $1.3 to $7.
The upgrade from Hold to Buy and the significant increase in the price target by Stifel analyst Benjamin Burnett indicate a positive outlook for eFFECTOR Therapeutics. This news is likely to have a positive short-term impact on the stock price as investors may see it as a signal to buy.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100